Cite
HARVARD Citation
Nie, W. et al. (n.d.). 318OBoth low and high blood tumour mutational burden are favourable predictors with atezolizumab. Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Nie, W. et al. (n.d.). 318OBoth low and high blood tumour mutational burden are favourable predictors with atezolizumab. Annals of oncology. p. . [Online].